Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers BV combined with Len + R demonstrated significant improvements in overall survival (OS; 37% reduced risk of ...

Dr Suchitra Sundaram describes critical disparities in DLBCL treatment, urging for equitable access to care and representation in clinical trials.

Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is ...

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper ...

Non-Hodgkin’s lymphoma is further divided into over 60 subtypes. B-cell lymphomas are the most common type of lymphoma ... However, when looking at T-cell lymphomas overall, the estimated five-year ...

17, 2024 — Researchers discovered they could boost survival to 92% for patients ... Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed ...

While the authors demonstrate an improvement in overall survival with ... diffuse large B-cell lymphoma; Len, lenalidomide; R, rituximab; R/R, relapsed/refractory; SCT, stem-cell transplant.

Higher toxicity rates also occurred. SAN DIEGO — Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings achieved worse survival ...

Lymphoma, a cancer of the lymphatic system, is grouped into two major types—Hodgkin’s and non-Hodgkin’s. Hodgkin’s lymphoma is a B-cell lymphoma ... five-year survival rate is 63%.